These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8538776)

  • 1. A good year for US biotech, but caution is still advised.
    Lehrman S
    Nature; 1996 Jan; 379(6562):194. PubMed ID: 8538776
    [No Abstract]   [Full Text] [Related]  

  • 2. Scientific commercialization. US biotech in good health.
    Gershon D
    Nature; 1991 Oct; 353(6347):785. PubMed ID: 1944544
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech bailout? A rescue of some sort will be needed to save a large subset of the US biotechnology industry.
    Nat Immunol; 2009 Jul; 10(7):667. PubMed ID: 19536186
    [No Abstract]   [Full Text] [Related]  

  • 4. Europe's biotech industry still losing to US, say analysts.
    Schiermeier Q
    Nature; 2001 May; 411(6836):404. PubMed ID: 11373636
    [No Abstract]   [Full Text] [Related]  

  • 5. Market heats up for US biotech companies.
    Gershon D
    Nature; 1991 May; 351(6322):86. PubMed ID: 2030734
    [No Abstract]   [Full Text] [Related]  

  • 6. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 7. Tough times set to continue for US biotech start-ups.
    Lehrman S
    Nature; 1999 Jan; 397(6716):191. PubMed ID: 9930684
    [No Abstract]   [Full Text] [Related]  

  • 8. US Supreme Court decision could compromise biotech patents.
    Robertson D
    Nat Biotechnol; 2001 May; 19(5):394. PubMed ID: 11328981
    [No Abstract]   [Full Text] [Related]  

  • 9. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 10. US biotech prepares to fight generic biologics.
    Reid B
    Nat Biotechnol; 2002 Apr; 20(4):322. PubMed ID: 11923820
    [No Abstract]   [Full Text] [Related]  

  • 11. US biotech firms line up for tax credits.
    Ledford H
    Nature; 2010 Jun; 465(7300):854-5. PubMed ID: 20559355
    [No Abstract]   [Full Text] [Related]  

  • 12. Biotech jobs are still around despite the recent bumpy ride.
    Smaglik P; Smith A
    Nature; 2002 Jul; 418(6893):4-5. PubMed ID: 12097871
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 14. 2007--a banner year for biotech.
    Lawrence S
    Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
    [No Abstract]   [Full Text] [Related]  

  • 15. New SEC regulations could hinder biotech investment. US Securities and Exchange Commission.
    Bouchie A
    Nat Biotechnol; 2002 Jul; 20(7):639-40. PubMed ID: 12089533
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech's perfect storm.
    Karberg S
    Cell; 2009 Aug; 138(3):413-5. PubMed ID: 19665960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Private biotech 2004--the numbers.
    Hodgson J
    Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 19. Placing a bet on biotech.
    Greenberg H
    Fortune; 2002 Dec; 146(13):188. PubMed ID: 12510567
    [No Abstract]   [Full Text] [Related]  

  • 20. A lifeline for the biotech sector.
    Kessel M
    Nat Biotechnol; 2009 Feb; 27(2):123-4. PubMed ID: 19204686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.